JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.

08/01/2025

Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".

JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.

Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.

Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.

HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th

Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.

Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.

HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th